# SEC-008: Penetration Test Summary Q3 2024

**Document ID:** SEC-008
**Version:** 1.0
**Date:** September 30, 2024
**Author:** Manus AI (on behalf of MedSync Health Security Team)
**Classification:** Confidential

---

## 1. Executive Summary

This document summarizes the findings and remediation status of the external and internal penetration test conducted on MedSync Health's core platforms during the third quarter of 2024 (Q3 2024). The testing was performed by an independent third-party security firm, SecurePath Consulting, between August 15, 2024, and September 15, 2024.

The primary objective was to assess the security posture of the in-scope systems against common attack vectors, specifically focusing on vulnerabilities that could compromise the confidentiality, integrity, or availability of Protected Health Information (PHI) and personally identifiable information (PII).

**Overall Risk Rating:** **Low**

The assessment identified no critical or high-severity vulnerabilities. Three medium-severity findings and four low-severity findings were reported. All medium-severity findings have been successfully remediated and verified as of the date of this report. This successful outcome reflects MedSync Health's strong commitment to its Information Security Management System (ISMS), which is certified under **ISO 27001 (Certified November 2022)**, and its adherence to regulatory frameworks.

## 2. Scope and Methodology

### 2.1. Scope of Assessment

The Q3 2024 penetration test focused on the following systems:

| System Component | Description | Test Type |
| :--- | :--- | :--- |
| **MedSync Connect API** (PROD-CONNECT) | Core integration service for hospital data exchange. | Gray-Box (Authenticated) |
| **MedSync Analytics Platform** (PROD-ANALYTICS) | Web application and underlying data warehouse. | Black-Box (Unauthenticated) |
| **External Network Perimeter** | Public-facing IP ranges, firewalls, and VPN endpoints. | External Network |
| **Internal Corporate Network** | Segmented network access for the Engineering department. | Internal Network |

### 2.2. Methodology

The testing methodology was based on industry best practices, including the **OWASP Top 10 (2021)** and the **NIST SP 800-115** technical guide. Specific attention was paid to controls relevant to **HIPAA Compliance (Certified March 2020)**, particularly those concerning access control, audit logging, and data transmission security.

## 3. Compliance Context

MedSync Health maintains a robust compliance framework to meet the stringent requirements of the healthcare and data privacy sectors. The Q3 2024 penetration test serves as a key control validation activity for several major compliance programs:

*   **SOC 2 Type II:** The successful completion of this test provides evidence for the **Security, Availability, and Confidentiality** Trust Services Criteria. The test was conducted shortly after the successful renewal of our SOC 2 Type II certification in **August 2024** (first certified August 2021).
*   **GDPR Compliance:** Findings related to data handling and access in the EMEA region (London, Berlin) were specifically reviewed against the principles of **GDPR (Implemented May 2020)**, ensuring that data minimization and pseudonymization controls are effective.
*   **ISO 27001:** The entire process, from scoping to remediation, followed the established procedures within our ISMS, certified in **November 2022**.

## 4. Key Findings and Remediation Status

A total of seven findings were identified. The table below summarizes the three medium-severity findings and their current status.

| ID | Severity | Finding Description | Affected System | Remediation Status |
| :--- | :--- | :--- | :--- | :--- |
| PT-008-01 | Medium | **Insecure Direct Object Reference (IDOR)** in PROD-ANALYTICS API endpoint `/api/v1/report/{id}` allowing unauthorized access to other user's report metadata by manipulating the report ID. | MedSync Analytics | **Remediated & Verified (Sept 25, 2024)**. Implemented row-level security checks. (See **SEC-011** for access control details) |
| PT-008-02 | Medium | **Missing HSTS Header** on the external load balancer for the MedSync Connect login portal, potentially allowing protocol downgrade attacks. | External Perimeter | **Remediated & Verified (Sept 20, 2024)**. HSTS header with `max-age=31536000; includeSubDomains; preload` configured. |
| PT-008-03 | Medium | **Outdated Library** in the internal network's deployment pipeline (Jenkins server) containing a known low-severity CVE (CVE-2024-XXXX). | Internal Network | **Remediated & Verified (Sept 28, 2024)**. Library updated to version 3.1.0. |

The four low-severity findings (e.g., verbose error messages, lack of rate limiting on a non-critical endpoint) have been documented and added to the backlog for resolution in Q4 2024, as per the risk acceptance policy defined in **SEC-001 (Information Security Policy)**.

## 5. Conclusion and Recommendations

The Q3 2024 penetration test confirms that MedSync Health's core systems maintain a strong security posture. The rapid and successful remediation of all medium-severity findings demonstrates the effectiveness of the Security Incident Response Team (SIRT) and the development lifecycle.

**Recommendations for Q4 2024:**

1.  **Address Low-Severity Findings:** Prioritize the four low-severity findings for resolution by the end of Q4 2024.
2.  **Increase Internal Testing:** Expand the scope of internal network testing in the next cycle to include all corporate segments, not just the Engineering department.
3.  **Review Incident Logs:** Review the findings in conjunction with recent internal security events. For detailed records of minor security events and their resolution, refer to **SEC-006 (Security Incident Reports)**.

This report is provided to the MedSync Health Board of Directors and relevant compliance officers to confirm the ongoing effectiveness of technical security controls.

---
*End of Document*
